|
Gene: RCBTB1 |
Gene summary for RCBTB1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RCBTB1 | Gene ID | 55213 |
Gene name | RCC1 and BTB domain containing protein 1 | |
Gene Alias | CLLD7 | |
Cytomap | 13q14.2 | |
Gene Type | protein-coding | GO ID | GO:0006325 | UniProtAcc | B3KR20 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55213 | RCBTB1 | HCC1_Meng | Human | Liver | HCC | 1.37e-20 | 9.72e-03 | 0.0246 |
55213 | RCBTB1 | HCC1 | Human | Liver | HCC | 3.76e-02 | 2.31e+00 | 0.5336 |
55213 | RCBTB1 | HCC2 | Human | Liver | HCC | 5.12e-09 | 2.52e+00 | 0.5341 |
55213 | RCBTB1 | S028 | Human | Liver | HCC | 2.94e-02 | 2.07e-01 | 0.2503 |
55213 | RCBTB1 | S029 | Human | Liver | HCC | 7.00e-04 | 3.13e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RCBTB1 | SNV | Missense_Mutation | c.89N>T | p.Ser30Leu | p.S30L | Q8NDN9 | protein_coding | tolerated(0.8) | benign(0.133) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
RCBTB1 | SNV | Missense_Mutation | c.323G>T | p.Gly108Val | p.G108V | Q8NDN9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A131-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
RCBTB1 | SNV | Missense_Mutation | c.497N>G | p.Ala166Gly | p.A166G | Q8NDN9 | protein_coding | tolerated(0.14) | possibly_damaging(0.887) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RCBTB1 | SNV | Missense_Mutation | c.1465N>C | p.Glu489Gln | p.E489Q | Q8NDN9 | protein_coding | deleterious(0.01) | benign(0.432) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
RCBTB1 | SNV | Missense_Mutation | rs749308756 | c.1124G>A | p.Arg375Gln | p.R375Q | Q8NDN9 | protein_coding | tolerated(0.63) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RCBTB1 | SNV | Missense_Mutation | c.82N>A | p.Gly28Ser | p.G28S | Q8NDN9 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-A6-5664-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | SD | |
RCBTB1 | SNV | Missense_Mutation | rs767930306 | c.1031N>A | p.Arg344His | p.R344H | Q8NDN9 | protein_coding | deleterious(0.02) | benign(0.066) | TCGA-AA-3506-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
RCBTB1 | SNV | Missense_Mutation | rs374135653 | c.355N>A | p.Val119Ile | p.V119I | Q8NDN9 | protein_coding | tolerated(0.56) | benign(0.001) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RCBTB1 | SNV | Missense_Mutation | novel | c.755N>A | p.Gly252Asp | p.G252D | Q8NDN9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RCBTB1 | SNV | Missense_Mutation | novel | c.80N>C | p.Phe27Ser | p.F27S | Q8NDN9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |